LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) $ in Thousands		1 Months Ended							3 Months Ended		6 Months Ended		48 Months Ended	80 Months Ended
	Oct. 01, 2014 USD ($)	Jun. 30, 2014 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Aug. 31, 2012 USD ($)	Nov. 30, 2008 item	Jul. 31, 2008 USD ($)	Jul. 31, 2005 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) item	Jun. 30, 2015 USD ($) item
License and collaborative arrangements
License and other revenue									$ 5,760			$ 17,520
Janssen Pharmaceutica N.V.
License and collaborative arrangements
Upfront fee received					$ 10,000
Mallinckrodt, Inc.
License and collaborative arrangements
Milestone payment received		$ 5,000	$ 10,000
Upfront fee received														$ 4,000
Number of products to be developed by utilizing Acuform technology | item						4
Upfront fee received for formulation work to be performed under the agreement														1,500
Milestone revenue recognized									5,000	$ 10,000
Number of products elected to develop | item						2
Upfront fees and milestones payment received														$ 27,500
Number of milestone payments received | item														4
Clinical development milestone payments														$ 500
Milestone payments following FDA's Acceptance											$ 10,000			$ 5,000
Ironwood Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fee received													$ 3,400
Milestone revenue recognized				$ 1,000
Number of milestone payments received | item													3
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Commercialization Agreement
License and collaborative arrangements
License and other revenue									400			700
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Promotion Agreement
License and collaborative arrangements
License and other revenue	$ 1,900
Upfront fee received							$ 12,000
Valeant Pharmaceuticals International, Inc.
License and collaborative arrangements
License and other revenue									$ 400			$ 800
Upfront fee received								$ 25,000
Valeant Pharmaceuticals International, Inc. | 1000mg Glumetza
License and collaborative arrangements
License and other revenue	$ 11,300